L. Sengeløv

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

M. Dror Michaelson, Stéphane Oudard, Yen-Chuan Ou et al. · Journal of Clinical Oncology · 2013 · 190 citations

Medicine, Oncology, Pharmacology +14

Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, with Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients with Bladder Cancer

Hans von der Maase, L. Sengeløv, J.T. Roberts et al. · The Journal of Urology · 2006 · 172 citations

Medicine, Oncology, Urology +6

Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer

J.T. Roberts, Hans von der Maase, L. Sengeløv et al. · Annals of Oncology · 2006 · 116 citations · Full text

Medicine, Oncology, Urology +7

Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study.

L. Sengeløv, Claus Kamby, Birthe Lund et al. · Journal of Clinical Oncology · 1998 · 85 citations

Medicine, Oncology, Pharmacology +16

Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC).

Yang Ou, M. Dror Michaelson, L. Sengeløv et al. · Journal of Clinical Oncology · 2011 · 56 citations

Medicine, Oncology, Pharmacology +17